Whitehawk Therapeutics, Inc. Common Stock WHWK
HEALTHCARE · BIOTECHNOLOGYi
Market datapartial · fetched 2026-11-18T01:20:49.543Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2027-01-15
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-17T21:11:58.415608764Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-18T01:20:48.404334+00:00
Whitehawk Therapeutics, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.79 | 422.7% | 60.8% | |||
| 25Δ | 3.12 | 393.1% | 54.6% | |||
| 30Δ | 3.44 | 363.5% | 48.5% | |||
| 35Δ | 3.76 | 333.9% | 42.3% | |||
| 40Δ | 4.08 | 304.3% | 36.1% | |||
| 45Δ | 4.40 | 274.7% | 29.9% | |||
| 50Δ | 4.72 | 245.1% | 23.7% | |||
| 55Δ | 5.05 | 218.0% | 18.0% | |||
| 60Δ | 5.45 | 208.6% | 15.3% | |||
| 65Δ | 5.85 | 199.2% | 12.7% | |||
| 70Δ | 6.26 | 189.8% | 10.1% | |||
| 75Δ | 6.66 | 180.4% | 7.5% | |||
| 80Δ | 7.06 | 171.0% | 4.8% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.79
- IV
- 422.7%
- B/E move
- 60.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.12
- IV
- 393.1%
- B/E move
- 54.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.44
- IV
- 363.5%
- B/E move
- 48.5%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.76
- IV
- 333.9%
- B/E move
- 42.3%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.08
- IV
- 304.3%
- B/E move
- 36.1%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.40
- IV
- 274.7%
- B/E move
- 29.9%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.72
- IV
- 245.1%
- B/E move
- 23.7%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.05
- IV
- 218.0%
- B/E move
- 18.0%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.45
- IV
- 208.6%
- B/E move
- 15.3%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 5.85
- IV
- 199.2%
- B/E move
- 12.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.26
- IV
- 189.8%
- B/E move
- 10.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 6.66
- IV
- 180.4%
- B/E move
- 7.5%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.06
- IV
- 171.0%
- B/E move
- 4.8%
Options history
History unavailable
Biotechnology
WVE
Wave Life Sciences Ltd., a clinical-stage genetic medicine company, designs, optimizes and produces new stereopure oligonucleotides through PRISM, a drug discovery and development…
More →XBIT
XBiotech Inc., a biopharmaceutical company, discovers, develops and markets True Human monoclonal antibodies for the treatment of various diseases. The company is headquartered in…
More →XENE
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, is dedicated to developing therapies to treat patients with neurological disorders in Canada. The company…
More →XFOR
X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of new therapies for the treatment of back…
More →XNCR
Description unavailable
More →ZBIO
Description unavailable
More →